Hisamitsu Pharmaceutical stock (JP3845000001): OTC rebound puts Salonpas maker back on US investors’ radar

Hisamitsu Pharmaceutical’s US OTC listing has rebounded sharply from penny-stock levels, drawing renewed attention to the Japanese pain?relief specialist behind the Salonpas brand and raising questions about what the move means for US investors.

Hisamitsu Pharmaceutical’s US over-the-counter stock has staged a sharp rebound from near-zero levels, with the HTSUY ADR recently changing hands around the mid?single?digit dollar range after an extreme percentage surge from penny?stock territory, according to Meyka as of 05/15/2026 and an overview note on Ad-hoc-news as of 05/15/2026. The move has put fresh focus on the Japanese pain?relief group and its Salonpas franchise among US retail investors who access the shares via the OTC Pink market.

As of: 05/16/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hisamitsu
• Sector/industry: Pharmaceuticals / consumer health
• Headquarters/country: Tosu, Japan
• Core markets: Japan, broader Asia, selected global markets including the US
• Key revenue drivers: Pain-relief patches and topical treatments under the Salonpas brand and related products
• Home exchange/listing venue: Tokyo Stock Exchange; US OTC Pink (ticker: HTSUY)
• Trading currency: Japanese yen in Tokyo, US dollars for the ADR

Hisamitsu Pharmaceutical: core business model

Hisamitsu Pharmaceutical is a Japanese healthcare company focused on transdermal and topical pain?relief products, with its best?known global brand being Salonpas, a line of medicated patches, sprays, and gels designed to relieve muscle and joint discomfort. The company also sells other external analgesics and prescription medicines, positioning itself at the intersection of pharmaceuticals and consumer health, according to company materials referenced in Ad-hoc-news as of 05/15/2026.

In Japan, Hisamitsu is a leading provider of medicated patches and related external medicines sold through pharmacies, drugstores, and hospitals, underpinning a relatively stable domestic revenue base. Internationally, the company has expanded Salonpas and associated products across Asia, parts of Latin America, and North America, pursuing a strategy of exporting its expertise in transdermal delivery systems to markets where consumers are increasingly looking for non?oral, non?opioid pain relief options, according to a corporate profile cited by Meyka as of 05/15/2026.

Beyond over?the?counter products, Hisamitsu also manufactures ethical pharmaceuticals and certain medical devices aimed at orthopedics and pain management, which are marketed mainly in Japan and selected Asian countries. This mix of consumer brands and prescription therapeutics provides diversification across channels and payers, giving the business exposure to both self?medication trends and physician?directed treatments, as discussed in the same overview by Meyka as of 05/15/2026.

Main revenue and product drivers for Hisamitsu Pharmaceutical

The Salonpas franchise remains Hisamitsu’s flagship revenue driver, encompassing medicated patches, plasters, and topical formulations targeting back pain, arthritis, and muscular aches. Flagship brands such as Salonpas, Salonsip, Mohrus, ByeBye?Fever, and Keplat form a portfolio of external analgesics and related therapies that generate significant sales in Japan and neighboring Asian markets, according to the business description in Meyka as of 05/15/2026.

Transdermal patches for prescription use, such as certain formulations of Mohrus indicated for pain management, provide an additional revenue stream subject to reimbursement and physician prescribing patterns. These products leverage Hisamitsu’s expertise in delivering active pharmaceutical ingredients through the skin over extended periods, which can help maintain steady drug concentrations and potentially improve tolerability relative to some oral regimens, according to technical descriptions summarized by Ad-hoc-news as of 05/15/2026.

Hisamitsu’s product development pipeline also includes fever?relief patches for children, topical treatments for minor injuries, and selected supplements, particularly tailored to Asian consumer preferences. While the revenue contribution of each newer product line is not broken out in the public summaries consulted, management materials indicate a continued emphasis on incremental innovation in patch technology and formulation updates, as well as geographic expansion through local partnerships, according to investor?facing documents on the company’s website referenced indirectly by Ad-hoc-news as of 05/15/2026.

Why Hisamitsu Pharmaceutical matters for US investors

For US investors, Hisamitsu provides exposure to Japan’s healthcare and consumer health markets via an American Depositary Receipt traded on the OTC Pink market under the HTSUY ticker, according to Meyka as of 05/15/2026. The underlying shares are listed on the Tokyo Stock Exchange, meaning that the ADR’s performance reflects not only company fundamentals but also movements in the Japanese yen relative to the US dollar.

The sharp OTC rebound has drawn attention because the percentage gain from a very low base appears extreme, with the ADR climbing to around $4.55 per share at one point in May 2026 after a spell of near?illiquidity, according to trading data summarized by Meyka as of 05/15/2026. For US retail traders, this highlights the risks associated with thinly traded OTC securities, where small absolute price changes can translate into very large reported percentage moves, particularly when quotes recover from distressed levels.

At the same time, Hisamitsu’s trading multiples are described as relatively moderate versus broader equity markets, with the ADR referenced as trading around 10 times earnings and below book value on a price?to?book basis as of mid?May 2026, according to the same analysis by Meyka as of 05/15/2026. For value?oriented US investors looking at international healthcare exposure, such metrics may be part of the appeal, alongside a balance sheet characterized by a high current ratio and low financial leverage in the cited materials.

Conclusion

Hisamitsu Pharmaceutical stands out as a Japanese specialist in topical and transdermal pain relief, anchored by the internationally recognized Salonpas brand and complemented by a portfolio of prescription patches and consumer health products. The recent rebound of its HTSUY ADR on the US OTC Pink market from near?penny levels has generated striking headline percentage gains but also underscores the volatility and liquidity risks inherent in thinly traded over?the?counter securities, according to trading commentary from Meyka as of 05/15/2026. For US investors evaluating the stock, key factors include the stability of Hisamitsu’s core pain?relief franchise, its financial profile as summarized in public data, and the additional layers of currency and market?structure risk associated with investing in a Japan?listed company via OTC instruments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.